Сартаны или ингибиторыангиотензинпревращающего фермента при ишемической болезни: что лучше?
Сартаны или ингибиторыангиотензинпревращающего фермента при ишемической болезни: что лучше?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004; 329: 1248–9.
2. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
3. McMurray J. Angiotensin receptor blockers and myocardial infarction. Analysis of evidence is incomplete and inaccurate. BMJ 2005; 330: 1269.
4. McDonald MA, Simpson SH, Ezekowitz JA et al. BMJ 2005; 331: 873.
5. Lee VC, Rhew DC, Dylan M et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693–704.
6. Strauss MH., Hall AS. Do angiotensin receptor blockers increase the risk of myocardial infarction? Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. Unraveling the ARB-MI Paradox. Circulation. 2006; 114: 838–54.
7. Strauss MH, Lonn EM, Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Eur Heart J 2005; 26: 2351–3.
8. Tsuyuki RT., McDonald MA. Angiotensin Receptor Blockers Do Not Increase Risk of Myocardial Infarction. Circulation 2006; 114: 855–60.
9. Verdeccia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26: 2381–6.
10. Hollenberg NK, Parving H-H, Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921–6.
11. Konstam MA, Neaton JD., Dickstein K et al. For the HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840–48.
12. Pitt B, ONeill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Amer J Cardiology 2001; 87: 1058–63.
13. Pitt B, Pfeffer MA, Domanski M et al. Prevention of events with angiotensine-converting enzyme inhibition: results of the PEACE study. New Engl J Med 2004; 35: 2058–117.
14. Swedberg K, Held P, Kjekshus J et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–84.
15. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665, doi: 10.1136/bmj.b1665.
16. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipil, or both in patients at high risk for vascular events. Engl J Med 2008; 358; 15: 1547–59.
17. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–39.
18. Sawada T, Yamada H, Dahlof B, Matsubara H. KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; 30: 2461–9.
19. Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 2009; 30: 2427–30.
20. Messerli FH, Bangalore S, Ram VS. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008; 359: 426–7, author reply 427.
21. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417–28.
22. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173–81.
23. Yusuf S, Teo K, Anderson C et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174–83.
24. Dagenais G, Yusuf S, Buorassa MG et al. HOPE investigators. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104: 522–6.
2. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
3. McMurray J. Angiotensin receptor blockers and myocardial infarction. Analysis of evidence is incomplete and inaccurate. BMJ 2005; 330: 1269.
4. McDonald MA, Simpson SH, Ezekowitz JA et al. BMJ 2005; 331: 873.
5. Lee VC, Rhew DC, Dylan M et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693–704.
6. Strauss MH., Hall AS. Do angiotensin receptor blockers increase the risk of myocardial infarction? Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. Unraveling the ARB-MI Paradox. Circulation. 2006; 114: 838–54.
7. Strauss MH, Lonn EM, Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Eur Heart J 2005; 26: 2351–3.
8. Tsuyuki RT., McDonald MA. Angiotensin Receptor Blockers Do Not Increase Risk of Myocardial Infarction. Circulation 2006; 114: 855–60.
9. Verdeccia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26: 2381–6.
10. Hollenberg NK, Parving H-H, Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921–6.
11. Konstam MA, Neaton JD., Dickstein K et al. For the HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840–48.
12. Pitt B, ONeill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Amer J Cardiology 2001; 87: 1058–63.
13. Pitt B, Pfeffer MA, Domanski M et al. Prevention of events with angiotensine-converting enzyme inhibition: results of the PEACE study. New Engl J Med 2004; 35: 2058–117.
14. Swedberg K, Held P, Kjekshus J et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–84.
15. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665, doi: 10.1136/bmj.b1665.
16. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipil, or both in patients at high risk for vascular events. Engl J Med 2008; 358; 15: 1547–59.
17. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–39.
18. Sawada T, Yamada H, Dahlof B, Matsubara H. KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; 30: 2461–9.
19. Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 2009; 30: 2427–30.
20. Messerli FH, Bangalore S, Ram VS. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008; 359: 426–7, author reply 427.
21. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417–28.
22. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173–81.
23. Yusuf S, Teo K, Anderson C et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174–83.
24. Dagenais G, Yusuf S, Buorassa MG et al. HOPE investigators. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104: 522–6.
Авторы
И.В.Фомин
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.